Astellas Pharma and Anokion said they will collaborate on research of new treatments for type 1 diabetes and celiac disease, and possibly a third indication, in a deal up to $760 million for Anokion, according to a GEN article.
The companies would create a new company, Kanyos Bio, to develop clinical candidates in type 1 diabetes and celiac disease, with Astellas holding an option to add a third autoimmune indication as part of the collaboration. Read the full story
